Medivir Dirección

Dirección controles de criterios 1/4

El CEO de Medivir es Jens Lindberg , nombrado en Jan 2022, tiene una permanencia de 2.42 años. compensación anual total es SEK7.82M, compuesta por 32.8% salario y 67.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.15% de las acciones de la empresa, por valor de SEK519.91K. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 0.8 años, respectivamente.

Información clave

Jens Lindberg

Chief Executive Officer (CEO)

SEK 7.8m

Compensación total

Porcentaje del salario del CEO	32.8%
Permanencia del CEO	2.4yrs
Participación del CEO	0.1%
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	less than a year

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jens Lindberg en comparación con los beneficios de Medivir?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-SEK 97m
Dec 31 2023	SEK 8m	SEK 3m	-SEK 89m
Sep 30 2023	n/a	n/a	-SEK 87m
Jun 30 2023	n/a	n/a	-SEK 78m
Mar 31 2023	n/a	n/a	-SEK 75m
Dec 31 2022	SEK 3m	SEK 2m	-SEK 89m

Compensación vs. Mercado: La compensación total de Jens($USD744.09K) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD354.03K).

Compensación vs. Ingresos: La compensación de Jens ha aumentado mientras la empresa no es rentable.

CEO

Jens Lindberg (53 yo)

2.4yrs

Permanencia

SEK 7,824,000

Compensación

Mr. Jens Lindberg serves as Chief Executive Officer at Medivir AB (publ) since January 24, 2022. He served as Acting Chief Executive Officer at Sedana Medical AB (publ) since June 1, 2021 until 2021 and se...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jens Lindberg	Chief Executive Officer	2.4yrs	SEK 7.82m	0.15% SEK 519.9k
Magnus Christensen	Chief Financial Officer	4.8yrs	SEK 2.66m	0.081% SEK 283.3k
Fredrik Öberg	Chief Scientific Officer	4.8yrs	sin datos	0.11% SEK 385.7k
Pia Baumann	Chief Medical Officer	1.3yrs	sin datos	0.086% SEK 298.9k
Karin Tunblad	Senior Principal Scientist & MIV-818 Project Leader	no data	sin datos	sin datos

3.6yrs

Permanencia media

55.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0GP7 se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lennart Hansson	Independent Director	6.1yrs	SEK 260.00k	0.036% SEK 124.5k
Uli Hacksell	Chairman of the Board	6.1yrs	SEK 690.00k	0.89% SEK 3.1m
Yilmaz Mahshid	Director	3.1yrs	SEK 260.00k	0.045% SEK 155.7k
Jeong-Woo Heo	Member of Scientific Advisory Council	less than a year	sin datos	sin datos
Bengt Westermark	Independent Director	7.1yrs	SEK 260.00k	0.029% SEK 99.6k
Jeffrey Evans	Member of Scientific Advisory Council	less than a year	sin datos	sin datos
Richard Finn	Member of Scientific Advisory Council	less than a year	sin datos	sin datos
Maria Reig	Member of Scientific Advisory Council	less than a year	sin datos	sin datos
Arndt Vogel	Member of Scientific Advisory Council	less than a year	sin datos	sin datos
Anna Torner	Director	less than a year	sin datos	sin datos
Angelica Loskog	Director	less than a year	sin datos	sin datos

0.8yrs

Permanencia media

74yo

Promedio de edad

Junta con experiencia: La junta directiva de 0GP7 no se considera experimentada (0.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Medivir Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Medivir AB (Publ) Appoints Nomination Committee

Medivir Aktiebolag (publ) Approves Board Appointments

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility

Medivir Aktiebolag (publ) Approves Board Appointments

High number of new and inexperienced directors

Full year 2023 earnings released: kr1.48 loss per share (vs kr1.59 loss in FY 2022)

High number of new and inexperienced directors

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

High number of new and inexperienced directors

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.27 loss in 3Q 2022)

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

High number of new and inexperienced directors

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Medivir AB Announces Patent Application for Fostrox Approval in China

New major risk - Revenue size

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

Medivir AB (publ), Annual General Meeting, May 05, 2021

Medivir AB Announces Delisting of Paid Subscription Shares

Medivir AB Enters into Licensing Agreement with Ubiquigent Limited for Preclinical Program USP7

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad